EUROPEAN JOURNAL OF CANCER Journal
Overview
publication venue for
- Phase 1b results from OP-1250-001, a dose escalation and dose expansion study of OP-1250, an oral CERAN, in subjects with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer (NCT04505826) 2022
- Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yes 2016
- Activity of rociletinib in EGFR mutant NSCLC patients with a history of CNS involvement 2015
- Updated efficacy and safety results from a global phase 2, open-label, single-arm study (NP28673) of alectinib in crizotinib-refractory ALK plus non-small-cell lung cancer (NSCLC) 2015
- Interim phase 2 results of study CO-1686-008: A phase 1/2 study of the irreversible, mutant selective, EGFR inhibitor rociletinib (CO-1686) in patients with advanced non small cell lung cancer 2014
- Phase 3 randomised study of canfosfamide (Telcyta (R), TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer. 45:2324-2332. 2009
- Phase II study of gemcitabine in patients with metastatic breast cancer 1997
Research
category
- ONCOLOGY Web of Science Category
Identity
International Standard Serial Number (ISSN)
- 0959-8049
Electronic International Standard Serial Number (EISSN)
- 1879-0852
Other
journal abbreviation
- EUR J CANCER